Nasdaq-traded Chinese herb company hits near $30 billion market value after speculative surge
Regencell Bioscience Holdings, an early-stage, Hong Kong-based bioscience company with no revenue, is the latest speculative overseas stock to attract an unusual surge in trading demand.
Shares of Regencell, which says it develops traditional Chinese herb treatments to treat childhood attention deficit hyperactivity disorder and autism, more than tripled on Monday — soaring more than 280% by the close. A 38-for-1 split declared on June 2 took effect on Monday.
The company's year to date performance is off the charts too, having risen 46,000% in 2025. By Monday's close, Regencell, founded in 2014 and traded on Nasdaq under the ticker 'RGC' since 2021, had a total market capitalization of $29.7 billion, according to S&P Capital IQ.
Regencell CEO Yat-Gai Au controls 86.24% of the total number of shares outstanding, according to FactSet data.
Regencell is the latest example of a speculative international stock attracting attention during summer trading. In August, 2022, for example, AMTD Digital, a Hong Kong-based fintech company, climbed 126%, briefly giving it a market value greater than Coca-Cola and Bank of America.
Regencell's market value is now about equal with Nasdaq-traded Lululemon and tops Super Micro Computer and Fifth Third Bancorp.
Earlier this month, Regencell explained the stock split as designed solely "to enhance liquidity in the market for the company's ordinary shares and make the shares more accessible to investors." Stock splits do not change anything fundamentally about a company.
Regencell's surge also came amid an increased focus on alternative medicines after Robert F. Kennedy Jr. was sworn in as Secretary of the U.S. Department of Health and Human Services in February. Kennedy, a vaccine skeptic, has taken steps to discourage routine immunizations in the U.S., last week removing all of the members of a panel that advises the Centers for Disease Control and Prevention on vaccines.
Regencell's stock often makes huge one-day swings. For example, shares jumped roughly 30% on March 21, before dropping 30% the following trading day.
In spite of the wild spike in the stock, little is known about the efficacy and commercialization of the Regencell's treatments for ADHD and Autistic Spectrum Disorders.
Regencell's business centers on a proprietary Traditional Chinese Medicine formula (TCM) developed in a partnership with TCM practitioner Sik-Kee Au using his "Sik-Kee Au TCM Brain Theory." Sik-Kee Au is the father of the Regencell chief executive officer Yat-Gai Au, the company said in a 2022 statement.
Three liquid-based, orally TCM formulae candidates claim to address mild, moderate and severe conditions and only contain natural ingredients such as so-called "detoxication herbs," blood circulation herbs and digestion herbs.
"These TCM formulae form the basis of our TCM product candidates, which we intend to develop and commercialize for the treatment of ADHD and ASD," Regencell's website reads.
In its latest annual report filed last October, Regencell said that it had not generated any revenue, nor filed for any regulatory approvals of its TCM formulas. For the fiscal years ended June 2024 and 2023, Regencell incurred total net losses of $4.36 million and $6.06 million, respectively, according to a 20F filing to the SEC.
"We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable," read the filing.
Regencell has not responded to a CNBC request for comment.
Regencell's latest patient case study, dated Nov. 15, 2023, said 28 patients were given the treatment over a period of three months in a second efficacy trial and showed an improvement in symptoms of ADHD and ASD, according to the company's webpage.
In an earlier case, Regencell said in a 2021 news release that it treated a dozen patients with suspected or confirmed Covid-19 cases, using a modified version of Au's modified proprietary cold and flu TCM formula. What was described as an improvement of Covid conditions led Regencell to form a joint venture with Honor Epic Enterprises Limited in Sept. 2021 to conduct further tests and commercialize the company's Covid treatment in ASEAN countries, according to the statement.
The stock has attracted little chatter on social media over the past few years. Those comments that have been made suggest both retail trader enthusiasm — and skepticism.
One user on the Reddit page "r/Shortsqueeze" wrote on Monday that Regencell is "trading like a meme coin. Bought a little to see what happens and it dropped 50% right after lol." Another user said in a post made three months ago, "I scalp RGC everyday for a bit of profit." The stock jumped 1,360% in May alone.
On LinkedIn in May, one investor said he "can't stop laughing," after reading the company description. Another post from a user in the pharmaceutical industry, according to his profile, last week said Regencell has become the "stock to watch" after its spike in May on "no official news or catalysts." Another LinkedIn user last month commented on Regencell, saying, "China based, low volume and no official news, bizarro."
On X, one user wrote in a Monday post said, "for #CompleteBullsh__CompanyOfTheYear I nominate regencell."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
5 minutes ago
- CNN
Trump's sons say his new phone will be built in the US. Experts say it looks a lot like a phone from China
When the Trump Organization unveiled its new Trump Mobile wireless service on Monday, it said its upcoming T1 smartphone will be 'proudly designed and built in the United States.' But experts told CNN they're skeptical that a smartphone can be built in the US based on the specifications, price and timeline laid out by Donald Trump, Jr., and Eric Trump, when they announced the phone. Experts pointed out striking similarities between the T1's specifications and an already available, Chinese-made phone. 'Unless the Trump family secretly built out a secure, onshore or nearshore (fabrication) operation over years of work without anyone noticing, it's simply not possible to deliver what they're promising,' said Todd Weaver, CEO of Purism, one of the only known companies to actually manufacture a cell phone in the United States. CNN has reached out to the Trump Organization for comment. President Donald Trump is not involved in the daily operations of the Trump Organization, which is run by the president's eldest sons, the company said in January. The announcement comes as the president has been pushing to bring manufacturing jobs back to the United States, particularly in the tech industry. He's pressured companies like Apple and Samsung to manufacture their phones in the US, saying companies who make their phones elsewhere will face a tariff of at least 25%. The Trump family say on Trump Mobile's website and in the formal announcement in Trump Tower on Monday that the phone will be 'Made in the USA.' But later, in a clip from an interview with conservative media personality Benny Johnson, Eric Trump said 'eventually all the phones can be built in the United States of America.' CNN has asked the Trump Organization whether the T1 phone will initially be built in the US. Both Weaver and a second expert, Max Weinbach, an analyst at market research firm Creative Strategies, independently told CNN they believe the T1 phone looks like a version of the already available Revvl 7 Pro 5G, made by China-based Wingtech, which provides manufacturing services for smartphones and other products. The phone retails for around $169 on Amazon. Weinbach and Weaver base this off the specifications listed by Trump Mobile, including the phone's body, battery and camera resolution. There's no direct evidence linking Trump's phone directly to the Revvl 7 Pro 5G or any specific phone made outside the US. CNN has reached out to Wingtech for comment. 'There (are) only realistically four or five smartphone ODM (original device manufacturers) that would actually be able to manufacture something like this,' Weinbach said. 'All of them are based out of China.' The Revvl device has the same screen size, battery capacity and storage as the T1 phone according to the information listed on the Trump Mobile website , and both phones have a headphone jack – a rare find on modern smartphones. However, the Revvl's camera is slightly different, and the T1 phone has more memory. Revvl's camera is slightly different, and the T1 phone has more memory. Another device labeled the Vtex Smart Phone listed on Made-in-China, a website for connecting buyers with Chinese suppliers, has specifications that are nearly identical to the T1's – including the same battery capacity, camera arrangement and supported software version, although it's unclear if the device has a headphone jack, and there are some differences in the memory and display. CNN has reached out to Shenzen Vitek Electronics Co., the company behind the Vtex Smart Phone, for comment. Weinbach says it's common for companies to customize devices made by ODMs before selling them under their own brand. 'A lot of them share the same components, parts, boards and antenna hardware,' he said. 'So, you can swap out a couple of things.' In a press release, the Trump Organization said Trump Mobile's products are not 'designed, developed, manufactured, distributed or sold by The Trump Organization or any of their respective affiliates or principals.' Building a phone in the US would be challenging, if not impossible, for a September 2025 launch in part because the US doesn't currently have the necessary fabrication plants, said Ryan Reith, Group Vice President for the International Data Corporation's Worldwide Device Tracker. And many of the components would likely still come from overseas. 'Any phone (that) is going to be sold in September, or shipped in September into the US, the majority of it's not going to be manufactured in the US,' said Reith. 'That's a given.' For example, Trump has pushed for months for Apple to build its signature product, the iPhone, in the United States. But that would mean a massive supply chain shift away from China and India. Nor would it mean just a change in factory resources – those countries also have highly specialized work forces that the US lacks. The result could mean price hikes or design changes for the iPhone, some analysts estimate. Weaver told CNN that sometime within the last year intermediaries working with the Trump Organization had been looking at Purism's phone and speaking to the company about what it takes to make a phone in the United States. Purism makes the $1,999 Liberty Phone, which touts itself as a secure 'Made in America' phone, although even they are forced to source some parts from abroad. 'There are certain areas where you're going to still need to have a global supply chain. One example is a crystal that goes in our GNSS chip or GPS chip. That single crystal is only manufactured in China,' Weaver said. Weaver pointed out the Federal Trade Commission has 'strict guidelines' on claiming an item is 'Made in the USA.' 'I do believe there will be a massive amount of back pedaling that goes on,' Weaver said. 'Just to manufacture a phone in the US with the chip sets you're actually getting, purchase and support with the US supply chain is a massive undertaking, and that's also the reason why we happen to be the only ones doing it.'
Boston Globe
6 minutes ago
- Boston Globe
A Boston-based lithium startup is building a US battery plant that will skirt Trump's tariffs
Advertisement The Boston-based company's move to build a pilot plant comes as President Donald Trump's administration sets the stage for tariffs on imports of key battery components from China. Pure Lithium says it extracts lithium from brine to manufacture a battery free of graphite, nickel, cobalt and manganese, allowing it to be produced without any inputs from China. The company received a letter of interest from the US Export-Import Bank in April for financing of as much as $300 million.
Yahoo
7 minutes ago
- Yahoo
3 Big Reasons FRSH Should Be On Your Watchlist
Over the last six months, Freshworks's shares have sunk to $15.55, producing a disappointing 7.6% loss while the S&P 500 was flat. This might have investors contemplating their next move. Given the weaker price action, is this a buying opportunity for FRSH? Find out in our full research report, it's free. Founded in Chennai, India in 2010 with the idea of creating a 'fresh' helpdesk product, Freshworks (NASDAQ: FRSH) offers a broad range of software targeted at small and medium-sized businesses. While reported revenue for a software company can include low-margin items like implementation fees, annual recurring revenue (ARR) is a sum of the next 12 months of contracted revenue purely from software subscriptions, or the high-margin, predictable revenue streams that make SaaS businesses so valuable. Freshworks's ARR punched in at $785.9 million in Q1, and over the last four quarters, its year-on-year growth averaged 19.9%. This performance was impressive and shows that customers are willing to take multi-year bets on the company's technology. Its growth also makes Freshworks a more predictable business, a tailwind for its valuation as investors typically prefer businesses with recurring revenue. Software is eating the world. It's one of our favorite business models because once you develop the product, it usually doesn't cost much to provide it as an ongoing service. These minimal costs can include servers, licenses, and certain personnel. Freshworks's gross margin is one of the highest in the software sector, an output of its asset-lite business model and strong pricing power. It also enables the company to fund large investments in new products and sales during periods of rapid growth to achieve outsized profits at scale. As you can see below, it averaged an elite 84.4% gross margin over the last year. Said differently, roughly $84.39 was left to spend on selling, marketing, and R&D for every $100 in revenue. While many software businesses point investors to their adjusted profits, which exclude stock-based compensation (SBC), we prefer GAAP operating margin because SBC is a legitimate expense used to attract and retain talent. This is one of the best measures of profitability because it shows how much money a company takes home after developing, marketing, and selling its products. Over the last year, Freshworks's expanding sales gave it operating leverage as its margin rose by 9.2 percentage points. Although its operating margin for the trailing 12 months was negative 15.5%, we're confident it can one day reach sustainable profitability. There are definitely things to like about Freshworks. After the recent drawdown, the stock trades at 5.6× forward price-to-sales (or $15.55 per share). Is now the time to initiate a position? See for yourself in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
